Phase Ib cohort 1 data of class I HDAC inhibitor 4SC-202 in combination with pembrolizumab in advanced cutaneous melanoma patients refractory or non-responding to prior anti-PD1 therapy
JOURNAL OF TRANSLATIONAL MEDICINE（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要